Sandu Pharmaceuticals Ltd.
Sandu Pharmaceutical
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹42.51 Cr.
| EX-Date | Purpose |
|---|---|
| 10 06 2021 | Inter alia, to consider the following 1. To consider and take note of the said demise of Shri Bhaskar G Sandu (DIN:02816792), Chairman of our company. 2. To consider and recommend appointment of Statutory Auditor 3. Any other matter with the permission of Chairman. |
| 30 06 2021 | Audited Results |
| 14 08 2021 | Quarterly Results & Dividend |
| 13 11 2021 | Quarterly Results |
| 29 11 2021 | Inter alia, to consider and approve Appointment of Internal Auditor for Mumbai at its Corporate Office |
| 14 02 2022 | Quarterly Results |
| 30 05 2022 | Audited Results |
| 07 07 2022 | Inter alia, to consider and approve : 1. To Consider and Reappoint CMA Shekhar Joshi & Co, Cost Accountants (Registration No. 100448) as Cost Auditor of the Company for the Financial Year 2022-23. 2. To Consider/Approve/Discuss on 03RD and Final Tranche, conversion of 8,50,326 nos of Equity Warrants Conversion into Equity Shares. 3. Any other matter. |
| 12 08 2022 | Quarterly Results & Dividend |
| 14 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 30 05 2023 | Audited Results |
| 14 08 2023 | Quarterly Results & Final Dividend |
| 13 11 2023 | Quarterly Results |
| 14 02 2024 | Quarterly Results |
| 30 03 2024 | Inter alia, to consider and approve: - 1. To Consider and Appoint Chief Financial Officer of the Company. 2. Any other matter with the permission of Chairman. |
| 14 11 2024 | Quarterly Results |
| 13 02 2025 | Quarterly Results |
| 28 05 2025 | Final Dividend & Audited Results |
| 13 08 2025 | Quarterly Results |
| 14 10 2025 | Inter alia, to consider the following :- 1. To Approve Notice of Postal Ballot for reclassification of M/s Akshath Finvest and Properties Private Limited from Promoter/ Promoter Group category to Public category pursuant to NOC received from Bombay Stock Exchange Limited dated 26 September 2025. 2. Any other matter with the permission of Chairman. |
| 12 11 2025 | Quarterly Results |
| 06 02 2026 | Quarterly Results |
| 05 05 2026 | Final Dividend & Audited Results |
